A federal court ruled Monday that Allergan’s patents for Restasis were invalid “based on obviousness,” opening the door to generic competition.
Patents for Restasis (cyclosporine ophthalmic emulsion 0.05%), Allergan’s dry eye drug that brings in $1.5 billion annually, were set to expire in 2014; however, the company filed additional patents extending protections to 2024.
The ruling from the U.S. District Court for the Eastern District of Texas found the defendants in the case — four generic pharmaceutical companies including Teva Pharmaceutical Industries —
Uncategorized